Nilotinib, Dasatinib Offer Similar Outcomes in CML Patients

A propensity score –matched comparison of two phase II trials found that dasatinib and nilotinib offer similar responses and outcomes as first-line therapy for patients with chronic-phase CML.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news